Insmed (NASDAQ:INSM) Insider Michael Alexander Smith Sells 2,159 Shares

Insmed, Inc. (NASDAQ:INSM) insider Michael Alexander Smith sold 2,159 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total transaction of $220,800.93. Following the completion of the transaction, the insider owned 39,454 shares in the company, valued at $4,034,960.58. This trade represents a 5.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Michael Alexander Smith also recently made the following trade(s):

• On Friday, May 22nd, Michael Alexander Smith sold 6,149 shares of Insmed stock. The stock was sold at an average price of $108.47, for a total transaction of $666,982.03.
• On Monday, March 30th, Michael Alexander Smith sold 19,638 shares of Insmed stock. The stock was sold at an average price of $150.98, for a total transaction of $2,964,945.24.

Insmed Price Performance

Shares of NASDAQ:INSM opened at $94.22 on Friday. The firm’s 50 day moving average price is $130.45 and its 200-day moving average price is $154.95. Insmed, Inc. has a twelve month low of $70.57 and a twelve month high of $212.75. The company has a quick ratio of 4.10, a current ratio of 4.47 and a debt-to-equity ratio of 0.80. The stock has a market capitalization of $20.42 billion, a PE ratio of -16.39 and a beta of 0.79.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.14. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. The firm had revenue of $305.96 million for the quarter, compared to analysts’ expectations of $300.81 million. During the same quarter in the prior year, the business earned ($1.42) EPS. The business’s quarterly revenue was up 229.7% on a year-over-year basis. Equities research analysts expect that Insmed, Inc. will post -2.56 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Raymond James Financial assumed coverage on shares of Insmed in a research note on Friday, April 10th. They issued an “outperform” rating and a $200.00 price objective on the stock. Stifel Nicolaus increased their price objective on shares of Insmed from $205.00 to $208.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. Mizuho increased their price objective on shares of Insmed from $204.00 to $206.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 25th. Roth Mkm reissued a “buy” rating and issued a $212.00 target price on shares of Insmed in a report on Friday, April 17th. Finally, HC Wainwright reissued a “buy” rating on shares of Insmed in a report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $210.50.

Institutional Investors Weigh In On Insmed

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in Insmed by 5.7% in the 4th quarter. Vanguard Group Inc. now owns 21,076,344 shares of the biopharmaceutical company’s stock worth $3,668,127,000 after acquiring an additional 1,140,524 shares in the last quarter. Darwin Global Management Ltd. increased its holdings in Insmed by 2.3% in the 4th quarter. Darwin Global Management Ltd. now owns 20,933,277 shares of the biopharmaceutical company’s stock worth $3,644,274,000 after acquiring an additional 475,832 shares in the last quarter. Capital International Investors increased its holdings in Insmed by 1.0% in the 3rd quarter. Capital International Investors now owns 7,553,853 shares of the biopharmaceutical company’s stock worth $1,087,830,000 after acquiring an additional 74,994 shares in the last quarter. State Street Corp increased its holdings in Insmed by 30.6% in the 4th quarter. State Street Corp now owns 5,201,744 shares of the biopharmaceutical company’s stock worth $905,312,000 after acquiring an additional 1,217,390 shares in the last quarter. Finally, Artisan Partners Limited Partnership increased its holdings in Insmed by 49.0% in the 3rd quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock worth $711,076,000 after acquiring an additional 1,623,342 shares in the last quarter.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.